Updates in Pediatric CNS Malignancies: Ependymoma, Germ Cell Tumors and Medulloblastoma - 2020 Annual Meeting
Over the last three years, results have been reported on large and/or national/international clinical trials in pediatric CNS tumors and radiotherapy. This course will update the learner on the important key points to note in how to treat ependymoma, germ cell tumors and medulloblasotma in the 21st century. Target definition, molecular classification and the use of systemic therapy will be addressed.
The activity is designed to meet the interests of radiation oncologists, radiation dosimetrists, and radiation oncology residents.
- Discuss the management of ependymoma.
- Explain the role of radiotherapy in treatment of CNS germ cell tumors.
- Determine the treatment course for medulloblastoma.
- Nicole A. Larrier, MD, MS is employed at Duke University Medical Center and has no financial relationships with a commercial interest.
- Thomas E. Merchant, DO, PhD is employed at St. Jude Children's Research Hospital and has investment interest from Philips Healthcare.
- Erin S. Murphy, MD is employed at Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic and has no financial relationships with a commercial interest.
- Tamara Z. Vern-Gross, DO, FAAP is employed at Department of Radiation Oncology, Mayo Clinic and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.